DOCSLIB.ORG

Magellan Complete Care of Virginia- MCC VA

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Magellan Complete Care of Virginia – MCC VA We cover both brand name drugs and generic drugs. Generic drugs have the same active-ingredient formula as a brand name drug. Generic drugs usually cost less than brand name drugs and are rated by the Food and Drug Administration (FDA) to be as safe and effective as brand name drugs. What is a Preferred Drug List? A Preferred Drug List is a list of covered drugs which represents the prescription therapies believed to be a necessary part of a quality treatment program. We will generally cover the drugs listed in our Preferred Drug List as long as the drug is medically necessary, the prescription is filled at a network pharmacy, and other plan rules are followed. For more information on how to fill your prescriptions, please review your Evidence of Coverage. How to Search For Drugs Use the alphabetical list to search by the first letter of your medication. Search by typing part of the generic (chemical) and brand (trade) names. How to Request an Exception You can ask us to make an exception to our coverage rules. There are several types of exceptions that you can ask us to make: You can ask us to cover your drug even if it is not on our Preferred Drug List. You can ask us to waive coverage restrictions or limits on your drug. You should contact us to ask us for an initial coverage decision for a Preferred Drug List or utilization restriction exception. When you are requesting a Preferred Drug List or utilization restriction exception you should submit a statement from your physician supporting your request. TIER DESCRIPTION T0 Covered OTC T1 Preferred Drugs T2 Non-Preferred Drugs TYPE DESCRIPTION There is a limit on the amount of this drug that is covered per QL Quantity Limit prescription, or within a specific time frame. This prescription drug may only be covered if you meet the AL Age Limit minimum or maximum age limit. Specialty drugs are high-cost drugs used to treat complex or rare conditions. Some examples of the diseases include; S Specialty Drug multiple sclerosis, rheumatoid arthritis, hepatitis C, and hemophilia. DC Drug Class Drug Class. PS Preferred Specialty Preferred Specialty. Your provider is required to get prior authorization before you fill your prescription, which ensures appropriate use of the PA PA Applies selected drug. Without prior approval, we may not cover this drug. QPD Quantity Per Day Quantity Per Day. IPC IPC - SPECIALTY PROGRAM IPC- Specialty Program. PAGE 2 LAST UPDATED 01/2021 PRODUCT DESCRIPTION TIER LIMITS & RESTRICTIONS ANALGESICS NONSTEROIDAL ANTI-INFLAMMATORY DRUGS ADDED STRENGTH HEADACHE T1 ADULT LOW DOSE ASPIRIN EC T0 ADVIL JUNIOR STRENGTH T0 ALL DAY PAIN RELIEF (CVS PAIN RLF 220 MG TB, GNP PAIN RLF 220 MG TB, PAIN RELIEF 220 MG TAB, PAIN RLF 220 T1 MG CAPLET, SM RELIEF 220 MG CAPLT, SM RELIEF 220 MG TAB) ALL DAY RELIEF T1 ANAPROX DS T2 PA ARTHROTEC 50 T2 PA ARTHROTEC 75 T2 PA ASPIR 81 T1 ASPIR-LOW T1 ASPIR-TRIN T1 aspirin (300 mg supp.rect, 600 mg supp.rect) T1 aspirin (81 mg tab chew, 81 mg tablet dr, 325 mg tablet, T1 325 mg tablet dr) aspirin (bayer 325 mg caplet, bayer 325 mg tablet, 500 mg tablet dr, bayer 500 mg caplet, bayer 500 mg tablet, T0 650 mg tablet dr) aspirin/calcium carbonate/magnesium T1 BAYER ADVANCED T0 BAYER CHEWABLE ASPIRIN T0 BAYER MIGRAINE T1 PAGE 3 LAST UPDATED 01/2021 PRODUCT DESCRIPTION TIER LIMITS & RESTRICTIONS CALDOLOR 800 MG/8 ML VIAL T2 PA QL 1 / day CAMBIA T2 PA QL 2 / day CELEBREX (50 MG CAPSULE, 200 MG CAPSULE) T2 PA QL 3 / day CELEBREX 100 MG CAPSULE T2 PA QL 1 / day CELEBREX 400 MG CAPSULE T2 PA celecoxib 100 mg capsule T1 QL 3 / day celecoxib 200 mg capsule T1 QL 2 / day QL 1 / day celecoxib 400 mg capsule T2 PA QL 2 / day celecoxib 50 mg capsule T2 PA CHILDREN'S MOTRIN T1 CHILDREN'S PROFEN IB T1 CHILDREN'S PROFENIB T1 choline salicyl/mag salicylate 500 mg/5ml liquid T2 PA DAYPRO T2 PA diclofenac potassium T2 PA diclofenac sodium 100 mg tab er 24h T2 PA diclofenac sodium (50 mg tablet dr, 75 mg tablet dr) T1 diclofenac sodium 25 mg tablet dr T1 diclofenac sodium/misoprostol (sodium/misoprostol 50 T2 PA tab ir dr, sodium/misoprostol 75 tab ir dr) PAGE 4 LAST UPDATED 01/2021 PRODUCT DESCRIPTION TIER LIMITS & RESTRICTIONS diflunisal 500 mg tablet T1 QL 3 / day DUEXIS T2 PA EC-NAPROSYN T2 PA ECOTRIN T0 ECPIRIN T1 etodolac (400 mg tab er 24h, 500 mg tab er 24h, 600 mg T2 PA tab er 24h) etodolac (200 mg capsule, 300 mg capsule, 400 mg tablet, T1 500 mg tablet) EXTRA PAIN RELIEF T1 EXTRAPRIN T1 FELDENE T2 PA fenoprofen calcium (200 mg capsule, 400 mg capsule, 600 T2 PA mg tablet) FENORTHO T2 PA FLANAX 220 MG TABLET T1 flurbiprofen (50 mg tablet, 100 mg tablet) T1 GOODY'S EXTRA STRENGTH T2 PA HEADACHE RELIEF T1 I-PRIN T1 IBU T1 IBU-200 T1 IBUPAK T2 PA PAGE 5 LAST UPDATED 01/2021 PRODUCT DESCRIPTION TIER LIMITS & RESTRICTIONS ibuprofen (50 mg/1.25 drops susp, 100 mg tablet, 100 mg/5ml oral susp, 200 mg capsule, 200 mg tablet, 400 mg T1 tablet, 600 mg tablet, 800 mg tablet) ibuprofen 100 mg tab chew T1 ibuprofen lysine/pf T2 PA QL 6 / day INDOCIN 25 MG/5 ML SUSPENSION T2 PA QL 4 / day INDOCIN 50 MG SUPPOSITORY T2 PA indomethacin (25 mg capsule, 50 mg capsule) T1 indomethacin 75 mg capsule er T2 PA indomethacin sodium T2 PA indomethacin, submicronized T2 PA INFANT'S MOTRIN T1 INFANTS PROFENIB T1 INFANTS' ADVIL T1 INFANTS' MOTRIN T1 ketoprofen (50 mg capsule, 75 mg capsule, 200 mg T2 PA cap24h pel) ketorolac tromethamine 15.75 mg spray T2 PA ketorolac tromethamine 10 mg tablet T1 QL 21 / fill ketorolac tromethamine (15 mg/ml cartridge, 15 mg/ml QL 40 / 23 days T2 vial) PA ketorolac tromethamine (30 mg/ml cartridge, 30 mg/ml QL 0.667 / DAY vial, 60 mg/2 ml cartridge, 60 mg/2 ml syringe, 60 mg/2 T2 ml vial) PA PAGE 6 LAST UPDATED 01/2021 PRODUCT DESCRIPTION TIER LIMITS & RESTRICTIONS ketorolac tromethamine (30 mg/ml syringe, 30mg/ml(1) QL 0.87 / DAY T2 vial) PA LODINE T2 PA meclofenamate sodium (50 mg capsule, 100 mg capsule) T2 PA MEDIPROXEN T1 QL 5 / day mefenamic acid 250 mg capsule T2 PA meloxicam (7.5 mg tablet, 15 mg tablet) T1 QL 1 / day MIDOL 220 MG CAPLET T1 MIGRAINE FORMULA T1 MIGRAINE RELIEF T1 QL 1 / day MOBIC T2 PA MOTRIN IB 200 MG CAPLET T1 nabumetone (500 mg tablet, 750 mg tablet) T2 PA NALFON (400 MG CAPSULE, 600 MG TABLET) T2 PA NAPRELAN (CR 375 MG TABLET, CR 500 MG TABLET) T2 PA QL 1 / day NAPRELAN CR 750 MG TABLET T2 PA NAPROSYN (125 MG/5 ML SUSPEN, 500 MG TABLET) T2 PA naproxen 125 mg/5ml oral susp T2 PA naproxen (250 mg tablet, 375 mg tablet, 375 mg tablet T1 dr, 500 mg tablet, 500 mg tablet dr) naproxen sodium (220 mg capsule, 220 mg tablet) T1 naproxen sodium (275 mg tablet, 375 mg tbmp 24hr, 500 T2 PA mg tbmp 24hr, 550 mg tablet) PAGE 7 LAST UPDATED 01/2021 PRODUCT DESCRIPTION TIER LIMITS & RESTRICTIONS QL 2 / day naproxen/esomeprazole magnesium T2 PA NEOPROFEN T2 PA oxaprozin 600 mg tablet T2 PA PAIN RELIEVER (RA RELIEVER TABLET, RELIEVER TABLET, T1 RELIEVR 250-250-65MG CPLT) PAIN RELIEVER PLUS T1 PAIN-OFF T1 AL Up to 75 yrs old piroxicam (10 mg capsule, 20 mg capsule) T2 PA PROFENO T2 PA PROVIL T1 AL At least 17 yrs old salsalate (500 mg tablet, 750 mg tablet) T2 PA SPRIX T2 PA ST. JOSEPH ASPIRIN T0 ST. JOSEPH ASPIRIN EC T0 sulindac (150 mg tablet, 200 mg tablet) T1 TIVORBEX T2 PA tolmetin sodium (200 mg tablet, 400 mg capsule, 600 mg T2 PA tablet) TRI-BUFFERED ASPIRIN 325 MG T1 QL 2 / day VIMOVO T2 PA QL 1 / day VIVLODEX T2 AL At least 18 yrs old PA PAGE 8 LAST UPDATED 01/2021 PRODUCT DESCRIPTION TIER LIMITS & RESTRICTIONS VOLTAREN-XR T2 PA WAL-PROFEN (200 MG CAPLET, 200 MG CAPSULE, 200 T1 MG SOFTGEL, 200 MG TABLET) WAL-PROXEN T1 QL 4 / day ZIPSOR T2 PA QL 3 / day ZORVOLEX T2 PA OPIOID ANALGESICS, LONG-ACTING QL 1 / day CONZIP (100 MG CAPSULE, 200 MG CAPSULE, 300 MG T2 DC LONG ACTING CAPSULE) OPIOIDS PA QL 6 / day DOLOPHINE HCL T2 DC LONG ACTING OPIOIDS PA QL 0.334 / day DURAGESIC T2 DC LONG ACTING OPIOIDS PA QL 0.334 / day fentanyl (12 mcg/hr patch td72, 25 mcg/hr patch td72, 50mcg/hr patch td72, 75mcg/hr patch td72, 100 mcg/hr T1 DC LONG ACTING OPIOIDS patch td72) PA hydrocodone bitartrate (10 mg cap er 12h, 15 mg cap er DC LONG ACTING 12h, 20 mg cap er 12h, 30 mg cap er 12h, 40 mg cap er T2 OPIOIDS 12h, 50 mg cap er 12h) PA QL 2 / day KADIAN (ER 10 MG CAPSULE, ER 20 MG CAPSULE, ER 50 T2 DC LONG ACTING MG CAPSULE, ER 100 MG CAPSULE) OPIOIDS PA PAGE 9 LAST UPDATED 01/2021 PRODUCT DESCRIPTION TIER LIMITS & RESTRICTIONS QL 1 / day KADIAN (ER 30 MG CAPSULE, ER 40 MG CAPSULE, ER 60 T2 DC LONG ACTING MG CAPSULE, ER 80 MG CAPSULE, ER 200 MG CAPSULE) OPIOIDS PA QL 6 / day methadone hcl (5 mg tablet, 10 mg tablet) T2 DC LONG ACTING OPIOIDS PA QL 2 / day morphine sulfate (10 mg cap er pel, 20 mg cap er pel, 50 T2 DC LONG ACTING mg cap er pel, 100 mg cap er pel) OPIOIDS PA QL 1 / day morphine sulfate (30 mg cap er pel, 60 mg cap er pel, 80 T2 DC LONG ACTING mg cap er pel) OPIOIDS PA morphine sulfate (30 mg cpmp 24hr, 40 mg cap er pel, 45 DC LONG ACTING mg cpmp 24hr, 60 mg cpmp 24hr, 75 mg cpmp 24hr, 90 T2 OPIOIDS mg cpmp 24hr, 120 mg cpmp 24hr) PA QL 4 / day morphine sulfate 15 mg tablet er T1 DC LONG ACTING OPIOIDS PA QL 3 / day morphine sulfate 30 mg tablet er T1 DC LONG ACTING OPIOIDS PA QL 2 / day morphine sulfate 60 mg tablet er T1 DC LONG ACTING OPIOIDS PA PAGE 10 LAST UPDATED 01/2021 PRODUCT DESCRIPTION TIER LIMITS & RESTRICTIONS QL 4 / day MS CONTIN ER 15 MG TABLET T2 DC LONG ACTING OPIOIDS PA QL 3 / day MS CONTIN ER 30 MG TABLET T2 DC LONG ACTING OPIOIDS PA QL 2 / day MS CONTIN ER 60 MG TABLET T2 DC LONG ACTING OPIOIDS PA tramadol hcl (100 mg cpbp 25-75, 100 mg tab er 24h, 100 QL
Recommended publications
  • Ceftazidime for Injection) PHARMACY BULK PACKAGE – NOT for DIRECT INFUSION

    Ceftazidime for Injection) PHARMACY BULK PACKAGE – NOT for DIRECT INFUSION

    PRESCRIBING INFORMATION FORTAZ® (ceftazidime for injection) PHARMACY BULK PACKAGE – NOT FOR DIRECT INFUSION To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibacterial drug for parenteral administration. It is the pentahydrate of pyridinium, 1-[[7-[[(2-amino-4­ thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1­ azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6α,7β(Z)]]. It has the following structure: The molecular formula is C22H32N6O12S2, representing a molecular weight of 636.6. FORTAZ is a sterile, dry-powdered mixture of ceftazidime pentahydrate and sodium carbonate. The sodium carbonate at a concentration of 118 mg/g of ceftazidime activity has been admixed to facilitate dissolution. The total sodium content of the mixture is approximately 54 mg (2.3 mEq)/g of ceftazidime activity. The Pharmacy Bulk Package vial contains 709 mg of sodium carbonate. The sodium content is approximately 54 mg (2.3mEq) per gram of ceftazidime. FORTAZ in sterile crystalline form is supplied in Pharmacy Bulk Packages equivalent to 6g of anhydrous ceftazidime. The Pharmacy Bulk Package bottle is a container of sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous use. THE PHARMACY BULK PACKAGE IS NOT FOR DIRECT INFUSION, FURTHER DILUTION IS REQUIRED BEFORE USE.
  • DHEA: Dehydroepiandrosterone

    DHEA: Dehydroepiandrosterone

    DHEA: Dehydroepiandrosterone Joseph Pepping, Pharm.D. [Am J Health-Syst Pharm 57(22):2048-2056, 2000. © 2000 ASHP, Inc.] Introduction Dehydroepiandrosterone (DHEA) and its active metabolite, DHEA sulfate (DHEAS), are endogenous hormones synthesized and excreted primarily by the zona reticularis of the adrenal cortex in response to adrenocorticotropic hormone. The exact mechanism of action and clinical role, if any, of DHEA and DHEAS remain unclear. Epidemiological data indicate an inverse relationship between serum DHEA and DHEAS levels and the frequency of cancer, cardiovascular disease (in men only), Alzheimer's disease and other age-related disorders, immune function, and progression of HIV infection. [1] Animal (primarily rodent) studies have suggested many beneficial effects of DHEA, including improved immune function and memory and prevention of atherosclerosis, cancer, diabetes, and obesity. Many of the benefits seen in animal studies have yet to be shown in humans. [1-3] Uses Clinically substantiated (yet still controversial) uses of DHEA include replacement therapy in patients with low serum DHEA levels secondary to chronic disease, adrenal exhaustion, or corticosteroid therapy; treating systemic lupus erythematosus (SLE), improving bone density in postmenopausal women; improving symptoms of severe depression; improving depressed mood and fatigue in patients with HIV infection; and increasing the rate of reepithelialization in patients undergoing autologous skin grafting for burns. [1,4-8] Other possible uses (with some supporting clinical studies) include enhancing the immune response and sense of well-being in the elderly, decreasing certain cardiovascular risk factors, and treating male erectile dysfunction. [4,8-12] Use of DHEA to slow or reverse the aging process, improve cognitive function, promote weight loss, increase lean muscle mass, or slow the progression of Parkinson's disease and Alzheimer's disease is clinically unsubstantiated.
  • Full Text in Pdf Format

    Full Text in Pdf Format

    DISEASES OF AQUATIC ORGANISMS Published July 30 Dis Aquat Org Oral pharmacological treatments for parasitic diseases of rainbow trout Oncorhynchus mykiss. 11: Gyrodactylus sp. J. L. Tojo*, M. T. Santamarina Department of Microbiology and Parasitology, Laboratory of Parasitology, Faculty of Pharmacy, Universidad de Santiago de Compostela, E-15706 Santiago de Compostela, Spain ABSTRACT: A total of 24 drugs were evaluated as regards their efficacy for oral treatment of gyro- dactylosis in rainbow trout Oncorhj~nchusmykiss. In preliminary trials, all drugs were supplied to infected fish at 40 g per kg of feed for 10 d. Twenty-two of the drugs tested (aminosidine, amprolium, benznidazole, b~thionol,chloroquine, diethylcarbamazine, flubendazole, levamisole, mebendazole, n~etronidazole,mclosamide, nitroxynil, oxibendazole, parbendazole, piperazine, praziquantel, roni- dazole, secnidazole, tetramisole, thiophanate, toltrazuril and trichlorfon) were ineffective Triclabenda- zole and nitroscanate completely eliminated the infection. Triclabendazole was effective only at the screening dosage (40 g per kg of feed for 10 d), while nitroscanate was effective at dosages as low as 0.6 g per kg of feed for 1 d. KEY WORDS: Gyrodactylosis . Rainbow trout Treatment. Drugs INTRODUCTION to the hooks of the opisthohaptor or to ulceration as a result of feeding by the parasite. The latter is the most The monogenean genus Gyrodactylus is widespread, serious. though some individual species have a restricted distri- Transmission takes place largely as a result of direct bution. Gyrodactyloses affect numerous freshwater contact between live fishes, though other pathways species including salmonids, cyprinids and ornamen- (contact between a live fish and a dead fish, or with tal fishes, as well as marine fishes including gadids, free-living parasites present in the substrate, or with pleuronectids and gobiids.
  • Product List March 2019 - Page 1 of 53

    Product List March 2019 - Page 1 of 53

    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
  • Exerts Anxiolytic-Like Effects Through GABAA Receptors in a Surgical Menopause Model in Rats

    Exerts Anxiolytic-Like Effects Through GABAA Receptors in a Surgical Menopause Model in Rats

    Biomedicine & Pharmacotherapy 109 (2019) 2387–2395 Contents lists available at ScienceDirect Biomedicine & Pharmacotherapy journal homepage: www.elsevier.com/locate/biopha Original article Chrysin (5,7-dihydroxyflavone) exerts anxiolytic-like effects through GABAA receptors in a surgical menopause model in rats T ⁎ Juan Francisco Rodríguez-Landaa,b, , Fabiola Hernández-Lópezc, Jonathan Cueto-Escobedoa, Emma Virginia Herrera-Huertad, Eduardo Rivadeneyra-Domínguezb, Blandina Bernal-Moralesa,b, Elizabeth Romero-Avendañod a Laboratorio de Neurofarmacología, Instituto de Neuroetología, Universidad Veracruzana, Xalapa, Veracruz, Mexico b Facultad de Química Farmacéutica Biológica, Universidad Veracruzana, Xalapa, Veracruz, Mexico c Hospital General de Zona con Medicina Familiar No. 28, Delegación Veracruz Norte, Instituto Mexicano del Seguro Social (H.G.Z. c/mf. No. 28, Delegación Veracruz Norte, IMSS), Martínez de la Torre, Veracruz, Mexico d Facultad de Ciencias Químicas, Universidad Veracruzana, Orizaba, Veracruz, Mexico ARTICLE INFO ABSTRACT Keywords: The present study investigated the effects of the flavonoid chrysin (5,7-dihydroxyflavone) on anxiety-like be- Anxiolytics havior in rats in a model of surgical menopause and evaluated the participation of γ-aminobutyric acid-A Chrysin (GABAA) receptors in these actions. At 12 weeks post-ovariectomy, the effects of different doses of chrysin (0.5, GABAA 1, 2, and 4 mg/kg) were evaluated in the elevated plus maze, light/dark test, and locomotor activity test, and Oophorectomy comparisons were made with the clinically effective anxiolytic diazepam. The participation of GABA receptors Ovariectomy A in the actions of chrysin was explored by pretreating the rats with the noncompetitive GABA chloride ion Surgical menopause A channel antagonist picrotoxin (1 mg/kg). The results showed that chrysin (2 and 4 mg/kg) reduced anxiety-like behavior in both the elevated plus maze and light/dark test, and these effects were similar to diazepam.
  • Totalcare Medicaid 2017 Q2 GB

    Totalcare Medicaid 2017 Q2 GB

    Preferred Drug List Molina Healthcare of New York, Inc. 2017 *Molina mandates the use of generic drugs, if available. Brand names listed are for reference only. THIS LIST IS SUBJECT TO CHANGE. You can get more information and updates to this document on our website at www.molinahealthcare.com MCD_CO_ESIPREFDRUGQ3_0817_08/27/2017 6025633NY0417 Table of Contents Anti - Infectives....................................................................................................................................................3 Antineoplastic / Immunosuppressant Drugs ......................................................................................................12 Autonomic / Cns Drugs, Neurology / Psych ......................................................................................................17 Cardiovascular, Hypertension / Lipids...............................................................................................................34 Dermatologicals/Topical Therapy......................................................................................................................41 Diagnostics / Miscellaneous Agents ..................................................................................................................56 Ear, Nose / Throat Medications..........................................................................................................................64 Endocrine/Diabetes ............................................................................................................................................66
  • Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation

    Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation

    www.sciencemag.org/cgi/content/full/327/5963/348/DC1 Supporting Online Material for Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation Jason Rihel,* David A. Prober, Anthony Arvanites, Kelvin Lam, Steven Zimmerman, Sumin Jang, Stephen J. Haggarty, David Kokel, Lee L. Rubin, Randall T. Peterson, Alexander F. Schier* *To whom correspondence should be addressed. E-mail: [email protected] (A.F.S.); [email protected] (J.R.) Published 15 January 2010, Science 327, 348 (2010) DOI: 10.1126/science.1183090 This PDF file includes: Materials and Methods SOM Text Figs. S1 to S18 Table S1 References Supporting Online Material Table of Contents Materials and Methods, pages 2-4 Supplemental Text 1-7, pages 5-10 Text 1. Psychotropic Drug Discovery, page 5 Text 2. Dose, pages 5-6 Text 3. Therapeutic Classes of Drugs Induce Correlated Behaviors, page 6 Text 4. Polypharmacology, pages 6-7 Text 5. Pharmacological Conservation, pages 7-9 Text 6. Non-overlapping Regulation of Rest/Wake States, page 9 Text 7. High Throughput Behavioral Screening in Practice, page 10 Supplemental Figure Legends, pages 11-14 Figure S1. Expanded hierarchical clustering analysis, pages 15-18 Figure S2. Hierarchical and k-means clustering yield similar cluster architectures, page 19 Figure S3. Expanded k-means clustergram, pages 20-23 Figure S4. Behavioral fingerprints are stable across a range of doses, page 24 Figure S5. Compounds that share biological targets have highly correlated behavioral fingerprints, page 25 Figure S6. Examples of compounds that share biological targets and/or structural similarity that give similar behavioral profiles, page 26 Figure S7.
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning

    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning

    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • NINDS Custom Collection II

    NINDS Custom Collection II

    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
  • Histamine Receptors

    Histamine Receptors

    Tocris Scientific Review Series Tocri-lu-2945 Histamine Receptors Iwan de Esch and Rob Leurs Introduction Leiden/Amsterdam Center for Drug Research (LACDR), Division Histamine is one of the aminergic neurotransmitters and plays of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit an important role in the regulation of several (patho)physiological Amsterdam, De Boelelaan 1083, 1081 HV, Amsterdam, The processes. In the mammalian brain histamine is synthesised in Netherlands restricted populations of neurons that are located in the tuberomammillary nucleus of the posterior hypothalamus.1 Dr. Iwan de Esch is an assistant professor and Prof. Rob Leurs is These neurons project diffusely to most cerebral areas and have full professor and head of the Division of Medicinal Chemistry of been implicated in several brain functions (e.g. sleep/ the Leiden/Amsterdam Center of Drug Research (LACDR), VU wakefulness, hormonal secretion, cardiovascular control, University Amsterdam, The Netherlands. Since the seventies, thermoregulation, food intake, and memory formation).2 In histamine receptor research has been one of the traditional peripheral tissues, histamine is stored in mast cells, eosinophils, themes of the division. Molecular understanding of ligand- basophils, enterochromaffin cells and probably also in some receptor interaction is obtained by combining pharmacology specific neurons. Mast cell histamine plays an important role in (signal transduction, proliferation), molecular biology, receptor the pathogenesis of various allergic conditions. After mast cell modelling and the synthesis and identification of new ligands. degranulation, release of histamine leads to various well-known symptoms of allergic conditions in the skin and the airway system. In 1937, Bovet and Staub discovered compounds that antagonise the effect of histamine on these allergic reactions.3 Ever since, there has been intense research devoted towards finding novel ligands with (anti-) histaminergic activity.
  • 209627Orig1s000

    209627Orig1s000

    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 209627Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review Reviewers of Multi-Disciplinary Review and Evaluation SECTIONS OFFICE/ AUTHORED/ ACKNOWLEDGED/ DISCIPLINE REVIEWER DIVISION APPROVED Mark Seggel, Ph.D. OPQ/ONDP/DNDP2 Authored: Section 4.2 Digitally signed by Mark R. Seggel -S CMC Lead DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, cn=Mark R. Signature: Mark R. Seggel -S Seggel -S, 0.9.2342.19200300.100.1.1=1300071539 Date: 2018.08.08 16:29:15 -04'00' Frederic Moulin, DVM, PhD OND/ODE3/DBRUP Authored: Section 5 Pharmacology/ Digitally signed by Frederic Moulin -S Toxicology DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, Reviewer Signature: Frederic Moulin -S 0.9.2342.19200300.100.1.1=2001708658, cn=Frederic Moulin -S Date: 2018.08.08 15:26:57 -04'00' Kimberly Hatfield, PhD OND/ODE3/DBRUP Approved: Section 5 Pharmacology/ Toxicology Digitally signed by Kimberly P. Hatfield -S DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, Team Leader Signature: Kimberly P. Hatfield -S 0.9.2342.19200300.100.1.1=1300387215, cn=Kimberly P. Hatfield -S Date: 2018.08.08 14:56:10 -04'00' Li Li, Ph.D. OCP/DCP3 Authored: Sections 6 and 17.3 Clinical Pharmacology Dig ta ly signed by Li Li S DN c=US o=U S Government ou=HHS ou=FDA ou=People Reviewer cn=Li Li S Signature: Li Li -S 0 9 2342 19200300 100 1 1=20005 08577 Date 2018 08 08 15 39 23 04'00' Doanh Tran, Ph.D.